ClinConnect ClinConnect Logo
Search / Trial NCT04412694

The Effect of Preoperative Oral Dexamethasone Supplementation on the Outcome of Thyroidectomised Patients.

Launched by MEDICAL UNIVERSITY OF LODZ · May 29, 2020

Trial Information

Current as of August 20, 2025

Unknown status

Keywords

Dexamethasone Hypocalcaemia Hypocalcemic Symptoms Postoperative Complications Vitamin D Deficiency Cytokines Postoperative Pain Postoperative Nausea Postoperative Vomiting Hoarseness Acute Phase Proteins Hypoparathyroidism

ClinConnect Summary

Recovery time after thyroid surgery may depend on several factors, such as postoperative pain, nausea and vomiting, postoperative sore throat, phonation disorders associated with recurrent laryngeal nerve palsy, and symptomatic postoperative hypocalcaemia associated with postoperative hypoparathyroidism.

Glucocorticoids are well known for their analgesic, anti-inflammatory, immunomodulatory and anti-emetic effects. However, there is little information in the literature on the prophylactic use of glucocorticosteroids in patients undergoing thyroid surgery. In some previous studies, preopera...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • patient's consent
  • adult patients
  • preoperative diagnosis of nontoxic multinodular goiter
  • total thyroidectomy
  • Exclusion Criteria:
  • lack of patient's consent
  • hyperthyroidism currently or in the past
  • retrosternal goiter
  • thyroid malignanacy or suspected malignant thyroid tumor
  • parathyroids disease
  • malingant tumor in any location currently or in the past
  • state after neck surgery
  • state after radiotherapy
  • bone diseases, osteoporosis
  • sarcoidosis
  • liver failure, hepatitis
  • kidney stones, kidney failure (eGFR\<60ml/min/1.73m2)
  • taking nonsteroidal anti-inflammatory drugs
  • steroid treatment
  • stomach and duodenal ulcer disease currently or in the past
  • active infection at the time of the study
  • history of tuberculosis
  • a period of 8 weeks before and 2 weeks after administration of the live vaccine
  • unregulated hypertension
  • diabetes
  • psychiatric disorders
  • glaucoma
  • corneal ulcers or corneal injuries
  • severe heart failure
  • pheochromocytoma
  • myasthenia gravis
  • epilepsy
  • head injury
  • ulcerative colitis
  • diverticulitis
  • pregnancy
  • breast-feeding
  • hypokalaemia
  • galactose intolerance
  • lactase deficiency
  • dexamethasone allergy, allergic to lactose, allergic to gelatinized starch, allergic to corn starch, allergic to colloidal anhydrous silica, allergic to magnesium stearate
  • allergic reaction to substances contained in the sweetener: sodium cyclamate, sodium saccharin, sodium bicarbonate, sodium citrate.
  • taking medications that affect calcium metabolism: anti-resorptive drugs, anabolic drugs, bisphosphonates, systemic glucocorticosteroids, thiazide diuretics, furosemide, proton pump inhibitors, antacids containing magnesium or aluminum salts, cholestyramine, colestipol, paraffin oil, salicylates, estrogen-containing oral contraceptives (hormonal contraceptives) , preparations containing calcium salts (regular intake), preparations of vitamin D or its analogues (regular intake)
  • taking medications that increase the side effect of dexamethasone or enter into drug interactions with dexamethasone: acetazolamide, loop diuretics, thiazide diuretics, diuretics, amphotericin B, glucocorticosteroids, mineralocorticosteroids, tetracosactide and laxatives, carbenoxolone, chlorokine, hydroxychlorokine and meflocin, angiotensin converting enzyme inhibitors, thalidomide, cholinesterase inhibitors in patients with myasthenia gravis, fluorochonolones, ephedrine, barbiturates, rifabutin, rifampicin, phenytoin and carbamazepine, aminoglutethimide, bile acid binding resins, such as cholestyramine, antacids,activated carbon, antifungal azoles, ketoconazole, HIV protease inhibitors, macrolide antibiotics, estrogens, anti-tuberculosis drugs (isoniazid), cyclosporin, praziquantel, oral anticoagulants (coumarin), atropine and other anticholinergic drugs, somatotropin, protirel.

About Medical University Of Lodz

The Medical University of Lodz is a leading academic institution dedicated to advancing healthcare through innovative research and clinical trials. With a strong focus on medical education, the university fosters collaboration among healthcare professionals, researchers, and students to enhance clinical practices and patient outcomes. Its commitment to excellence in scientific inquiry and patient care positions it as a pivotal sponsor of clinical trials, aimed at translating research findings into practical applications that benefit diverse populations. Through rigorous methodologies and ethical standards, the Medical University of Lodz contributes significantly to the global medical community and the development of new therapeutic interventions.

Locations

łódź, łódzkie, Poland

łódź, , Poland

Patients applied

0 patients applied

Trial Officials

Anna Grzegory, MD

Principal Investigator

Medical University of Lodz, Poland

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials